LEVOFLOXACIN LACTATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H20FN3O4.C3H6O3
Molecular Weight	451.4454
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 2
E/Z Centers	0
Charge	0
Stereo Comments	C3 H6 O3

SHOW SMILES / InChI

Structure Search

SMILES

CC(O)C(O)=O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4

InChI

InChIKey=ONDRRTIAGBDDKP-PPHPATTJSA-N

InChI=1S/C18H20FN3O4.C3H6O3/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;1-2(4)3(5)6/h7-8,10H,3-6,9H2,1-2H3,(H,24,25);2,4H,1H3,(H,5,6)/t10-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C3H6O3
Molecular Weight	90.0779
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 59 Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786	Inhibitor 8146
DNA gyrase 26 Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538	Inhibitor 8146

Conditions

Condition	Modality	Highest Phase	Product
Pneumonia 90 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11
Complicated Skin and Skin Structure Infections 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11
Chronic bacterial prostatitis 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11
Plague 14 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11
Chronic bronchitis 49 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11
Urinary tract infections 202 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020634s068,020635s074,021721s035lbl.pdf	Curative	Approved 8307	LEVAQUIN Approved Use LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date 8.5104001E11

C_max

Value	Dose	Analyte	Population
7.9 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
11.8 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.85 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2.04 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.3 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
49.6 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
118 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
111 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
19.88 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
55.3 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
7.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.4 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
5.97 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6.6 h REVIEW https://pubmed.ncbi.nlm.nih.gov/9068926	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	LEVOFLOXACIN unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19	Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf Page: 19

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532 substrate 1670	inhibitor 1695 substrate 985	inhibitor 1789 substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2B6 770 CYP2C8 869 CYP2C19 1410 OCTN2 66	CYP1A2 1013 CYP2C19 955 UGT1A1 417 UGT1A3 421 UGT1A4 345 UGT1A6 306 UGT1A7 235 UGT1A8 282 UGT1A10 289 OATP1A2 59 OATP2B1 103 OATP1B1 389 OATP1B3 333 P-gp 1491 BCRP 545

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	inconclusive	levofloxacin-N-oxide 6
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	no
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2B6 946	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C8 923	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	weak	levofloxacin-N-oxide 6
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: -	yes [IC50 210 uM]
OCTN2 71	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: -	yes [IC50 6800 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	yes	levofloxacin-N-oxide 6

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C19 955	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2C9 985	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP2D6 1168	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
CYP3A4 1670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: -	no	levofloxacin-N-oxide 6
OATP1B1 389	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP1B3 333	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
OATP2B1 103	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	no
UGT1A10 289	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A4 345	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A6 306	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
UGT1A8 282	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	no
OATP1A2 59	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17274666/ Page: -	yes [Km 136 uM]
BCRP 545	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17978494/ Page: -	yes
UGT1A1 417	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A3 421	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes
UGT1A7 235	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/15769885/ Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: -

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-6360	http://www.3bsc.com/index/pro_info.php?id=122847
3B Scientific (Wuhan) Corp	3B1-01436	http://www.3bsc.com/index/pro_info.php?id=21648
AA Blocks	AA0003AY	http://www.aablocks.com/goods/Goods/detail?id=AA0003AY
AEchem Scientific Corp., USA	AE020182	http://www.aechemsc.com/info_products/AE020182.php
Aaron Chemicals	AR00042Q	http://www.aaronchem.com/100986-85-4
Achemtek	0104-018860	http://www.achemtek.com/100986-85-4
Achemtek	0104-011027	http://www.achemtek.com/138199-71-0
Acorn PharmaTech	ACN-038325	http://www.acornpharmatech.com/
Alsachim	853	http://www.alsachim.com/product-C2615-glo.bal-view.html
Ambinter	Amb20669810	http://www.ambinter.com/reference/20669810
Ambinter	Amb2444040	http://www.ambinter.com/reference/2444040
ApexBio Technology	B1959	http://www.apexbt.com/levofloxacin.html
ApexBio Technology	A5511	http://www.apexbt.com/ofloxacin.html
Aurora Fine Chemicals LLC	A17.890.330	http://online.aurorafinechemicals.com/info?ID=A17.890.330
BLD Pharm	BD0022	http://www.bldpharm.com/products/100986-85-4.html
BioSynth	Q-201295	https://www.biosynth.com/en/products/life-science/culture-media-additives/products/Q-201295.html
CSNpharm	CSN10001	https://www.csnpharm.com/products/levofloxacin.html
Chem Scene	CS-2218	http://www.chemscene.com/100986-85-4.html
ChemMol	30101095	http://www.chemmol.com/chemmol/30101095.html
ChemMol	49401467	http://www.chemmol.com/chemmol/49401467.html
Chemenu	CM110290	http://www.chemenu.com/products/CM110290
Chemspace	CSSB00016993440	https://chem-space.com/CSSB00016993440
Clearsynth	CS-O-01741	http://www.clearsynth.com/en/CSO01741.html
DC Chemicals	DCAPI1002	http://www.dcchemicals.com//product_show-Levofloxacin_Levaquin_.html
Excenen	EX-A1488	http://www.excenen.com/searchresultlist.php?id=100986-85-4
Hairui	HR127302	http://www.hairuichem.com/en/product/100986-85-4.html
LGC Standards	DRE-C14629730	https://www.lgcstandards.com/US/en/p/DRE-C14629730
LGC Standards	LGCFOR0846.00	https://www.lgcstandards.com/US/en/p/LGCFOR0846.00
LGC Standards	MM0846.00	https://www.lgcstandards.com/US/en/p/MM0846.00
Lab Network	LN00235793	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00235793
MedChem Express	HY-B0330	https://www.medchemexpress.com/Levofloxacin.html
MuseChem	I000113	https://www.musechem.com/product/I000113.html
OChem	3793	http://www.ocheminc.com/index.php?act=psearch&pid=986L854
Otava	12488923	https://search.otavachemicals.com/#!/search?query=12488923&type=code&base=dbb
Sigma-Aldrich	L-038_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/l038?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	40922_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/40922?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	28266_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/28266?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S061060	http://www.sinfoobiotech.com/product/1064463
Smolecule	S532946	http://www.smolecule.com/products/s532946
TCI (Tokyo Chemical Industry)	L0193	http://www.tcichemicals.com/eshop/en/us/commodity/L0193/index.html
THE BioTek	bt-273347	https://www.thebiotek.com/product/inhibitors/bt-273347
VladaChem	VL261985-25G	https://www.vladachem.com/product.php?products=100986-85-4
Yuhao Chemical	LT1250	http://www.chemyuhao.com/100986-85-4.html
abcr GmbH	AB250203	http://www.abcr.com/shop/en/AB250203
eNovation Chemicals	D674497	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674497
eNovation Chemicals	Y1040229	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1040229
iChemical	EBD8264	http://www.ichemical.com/products/100986-85-4.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-2011834955	https://mcule.com/MCULE-2011834955/

PubMed

Title	Date	PubMed
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.	1999 Dec	10582897
Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening.	2000 Oct	10991858
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.	2000 Sep	11185410
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.	2001	11447768
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].	2001 Apr	11398326
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.	2001 Apr	11379965
[Injectable quinolones].	2001 Apr	11305008
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.	2001 Apr	11296178
Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.	2001 Apr	11266418
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration.	2001 Feb	11396281
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.	2001 Feb	11157911
[In vitro antimycobacterial activities of a new quinolone, balofloxacin].	2001 Jan	11211780
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.	2001 Jan	11152428
Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.	2001 Jan	11125032
Use of a recombinant strain of Mycobacterium avium expressing beta-galactosidase to evaluate the activities of antimycobacterial agents inside macrophages.	2001 Jan	11120998
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department.	2001 Jul	11446525
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.	2001 Jul	11418525
Activity of levofloxacin and ciprofloxacin against urinary pathogens.	2001 Jul	11418511
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece.	2001 Jun	11397616
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.	2001 Jun	11397615
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.	2001 Mar	11406752
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.	2001 Mar	11318077
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.	2001 Mar	11172695
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.	2001 Mar-Apr	11173811
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.	2001 May	11370709
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.	2001 May	11328803
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.	2001 May	11328779
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.	2001 Spring	11310802

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.

Route of Administration: Other

In Vitro Use Guide

Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.

Substance Class	Chemical Created by `admin` on `Sat Dec 17 23:13:07 UTC 2022` Edited by `admin` on `Sat Dec 17 23:13:07 UTC 2022`
Record UNII	NHR291QA18
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOFLOXACIN LACTATE

Common Name

English

7H-1,4-OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, COMPD. WITH 2-HYDROXYPROPANOIC ACID (1:1)

Systematic Name

English

PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH (3S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID (1:1)

Systematic Name

English

(3S)-9-FLUORO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-2,3-DIHYDRO-7H-(1,4)OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXYLIC ACID - 2-HYDROXYPROPANOIC ACID (1:1)

Systematic Name

English

7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, MONO(2-HYDROXYPROPANOATE)

Systematic Name

English

7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (3S)-, 2-HYDROXYPROPANOATE (1:1)

Systematic Name

English

Levofloxacin Lactate [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

97853-07-1